TNFSF10 and central nervous system cancer: Consistent work by different groups of investigators showed indeed that both BM-derived and AT-derived MSCs are capable of inducing the tumor shrinkage in xenografted human glioma [11], gastric [12] or pancreatic [13] cancers, as well as in melanoma [14], and that this native anti-tumor cell growth activity may be definitely enhanced with MSCs transduced to express the tumor necrosis factor related apoptosis inducing ligand (TRAIL), namely a pro-apoptogen molecule linking the death receptors (DR) 4 and 5 on cancer cells [15].